Drake Neil 4
4 · OBALON THERAPEUTICS INC · Filed Feb 5, 2018
Insider Transaction Report
Form 4
Drake Neil
VP of Research and Development
Transactions
- Exercise/Conversion
Common Stock
2018-02-02$1.83/sh+5,746$10,515→ 13,899 total - Exercise/Conversion
Common Stock
2018-02-02$1.77/sh+4,310$7,629→ 21,850 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-02-02−229→ 0 totalExercise: $1.31From: 2014-10-08Exp: 2021-01-26→ Common Stock (229 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-02-02−5,746→ 0 totalExercise: $1.83From: 2016-06-14Exp: 2022-08-14→ Common Stock (5,746 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-02-02−4,310→ 6,034 totalExercise: $1.77Exp: 2026-05-11→ Common Stock (4,310 underlying) - Exercise/Conversion
Common Stock
2018-02-02$1.31/sh+229$300→ 8,153 total - Exercise/Conversion
Common Stock
2018-02-02$0.76/sh+3,641$2,767→ 17,540 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-02-02−3,641→ 1,083 totalExercise: $0.76Exp: 2025-03-04→ Common Stock (3,641 underlying)
Footnotes (2)
- [F1]This option vests as to 25% of the total shares on January 1, 2016, then 2.083% monthly, with 100% of the total shares vested on January 1, 2019, subject to the reporting person's provision of service to the Issuer on each vesting date.
- [F2]This option vests as to 2.083% of the total shares monthly, commencing on May 11, 2016, with 100% of the total shares vested on May 11, 2020, subject to the reporting person's provision of service to the Issuer on each vesting date.